Rank 34 • MedTech & Devices
Beta Bionics
Develops the iLet Bionic Pancreas, an autonomous, insulin-delivery system requiring minimal manual input from diabetes patients.
Visit website- Signal Score
- 89.1
- Total raised
- $270M
- Stage
- Series D+
- Founded
- 2015
- Headquarters
- Concord, United States
- Region
- North America
Their signal
Beta Bionics is transforming diabetes care with its cleared autonomous system that determines insulin doses using only body weight. Its highly successful commercialization path addresses massive global clinical needs.
Signal Score 89.1editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in MedTech & Devices
Figures are subjective research desk estimates compiled from public sources and refreshed daily, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.